OncoCyte Corporation

OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

The company believes that better and earlier detection of cancer through liquid biopsies will:

  • Improve patient outcomes
  • Increase the life expectancy of cancer patients
  • Significantly reduce health care costs

Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.

These invasive tests are expensive, time-consuming when time may be of utmost importance, and lead to both patient anxiety and physician uncertainty about the diagnosis.

Our next generation liquid biopsy diagnostics will use blood or urine samples to detect the presence or absence of cancer. These diagnostics are:

  • Simple
  • Accurate
  • Fast
  • Non-invasive

OncoCyte’s initial focus is on cancers with large patient populations and significant unmet need.

Alameda, US
Size (employees)
15 (est)
OncoCyte Corporation is headquartered in Alameda, US

OncoCyte Corporation Office Locations

OncoCyte Corporation has an office in Alameda
Alameda, US (HQ)
102 1010 Atlantic Ave

OncoCyte Corporation Data and Metrics

OncoCyte Corporation Financial Metrics

$, USD

Net income (FY, 2016)

(11.2 m)

EBIT (FY, 2016)

(11.1 m)

Market capitalization (23-Jun-2017)

158.6 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

10.2 m
OncoCyte Corporation's current market capitalization is $158.6 m.
$, USDFY, 2016

R&D expense

5.7 m

General and administrative expense

5.5 m

Operating expense total

11.1 m


(11.1 m)

Interest expense

(28 k)

Net Income

(11.2 m)
$, USDFY, 2016


10.2 m

Accounts Receivable

14.3 m


285 k

Current Assets

12.7 m

Total Assets

14.4 m

Accounts Payable

422 k

Current Liabilities

4.3 m

Retained Earnings

(35.3 m)

Total Equity

9.9 m

Financial Leverage

1.5 x
$, USDFY, 2016

Net Income

(11.2 m)

Depreciation and Amortization

145 k


101 k

Cash From Operating Activities

(7.5 m)

Purchases of PP&E

(106 k)

Cash From Investing Activities

(181 k)

Cash From Financing Activities

9.9 m
Y, 2016

Financial Leverage

1.5 x

OncoCyte Corporation Operating Metrics

FY, 2016

Patent Families


Patents Issued


OncoCyte Corporation Market Value History

OncoCyte Corporation Online and Social Media Presence

OncoCyte Corporation Company Life and Culture

You may also be interested in